Northwest Biotherapeutics Closes $13.8M Offering
Northwest Biotherapeutics, Inc. (Nasdaq: NWBO; NWBOW), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 450,000 shares of common stock and warrants to purchase 225,000 shares, at a public offering price of $4.00 per share and $0.01 per warrant in connection with its previously announced underwritten public offering of 3,000,000 shares of common stock and warrants to purchase 1,500,000 shares of common stock, bringing total gross proceeds from the offering to $13.8 million.
The Warrants have a per share exercise price of $5.00, are exercisable immediately, and expire 5 years from the date of issuance.
Aegis Capital Corp. is acting as the sole book-running manager for this offering.
Citybizlist Partner News
- Adelberg, Rudow, Dorf & Hendler, LLC - A Conversation with Sonia Socha, Executive Director, SBLC - Part I
- Rosenberg Martin Greenberg, LLP - Dave Troy Got It Right On The GBTC
- St. John Properties - 2013 Recap: Leases More Than 1.2M Square Feet Of New Space
- MacKenzie - MacKenzie Closes 7521 Pulaski Highway Industrial Sale